128 related articles for article (PubMed ID: 37838563)
41. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
[TBL] [Abstract][Full Text] [Related]
42. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation.
Ozkurt ZN; Yegin ZA; Suyani E; Aki SZ; Acar K; Yagci M; Sucak GT
J Clin Apher; 2010; 25(5):280-6. PubMed ID: 20623783
[TBL] [Abstract][Full Text] [Related]
43. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
44. Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
Choi HY; Yong CS; Yoo BK
Ann Pharmacother; 2010 Jan; 44(1):117-26. PubMed ID: 20009003
[TBL] [Abstract][Full Text] [Related]
45. A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.
Renfroe H; Arnold M; Vaughn L; Harvey RD; Hamilton E; Lonial S; Khoury HJ; Kaufman JL; Lechowicz MJ; Flowers CR; Waller EK
Transfusion; 2011 Aug; 51(8):1779-83. PubMed ID: 21332729
[TBL] [Abstract][Full Text] [Related]
46. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
Ding X; Huang W; Peng Y; Fan H; Zhu Y; Liu X; Yang Y; Guo Q; Qiu L; Dai Y; Zou D; Jin F
Ann Hematol; 2020 Jun; 99(6):1331-1339. PubMed ID: 32382775
[TBL] [Abstract][Full Text] [Related]
47. A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.
Ghobadi A; Fiala MA; Rettig M; Schroeder M; Uy GL; Stockerl-Goldstein K; Westervelt P; Vij R; DiPersio JF
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):e588-e593. PubMed ID: 31358485
[TBL] [Abstract][Full Text] [Related]
48. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Kumar S; Munshi NC; Dispenzieri A; Kyle R; Merlini G; San Miguel J; Ludwig H; Hajek R; Jagannath S; Blade J; Lonial S; Dimopoulos MA; Einsele H; Barlogie B; Anderson KC; Gertz M; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Richardson PG; Niesvizky R; Rajkumar SV; Durie BG;
Leukemia; 2009 Oct; 23(10):1904-12. PubMed ID: 19554029
[TBL] [Abstract][Full Text] [Related]
49. The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
Moreb JS; Lantos L; Chen F; Elliott K; Dugan J; Skarbnik AP; Kropf PL; Ward K
Transfus Apher Sci; 2023 Dec; 62(6):103787. PubMed ID: 37704508
[TBL] [Abstract][Full Text] [Related]
50. Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.
Damron EP; Qazilbash MH; Fang PQ; Wu SY; Dabaja BS; Rondon G; Hosing C; Champlin RE; Bashir Q; Shpall EJ; Knafl MK; Lee HC; Manasanch EE; Patel K; Thomas SK; Orlowski RZ; Weber DM; Pinnix CC; Gunther JR
Transplant Cell Ther; 2023 Jan; 29(1):37.e1-37.e7. PubMed ID: 37753818
[TBL] [Abstract][Full Text] [Related]
51. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
Herbert KE; Demosthenous L; Wiesner G; Link E; Westerman DA; Came N; Ritchie DS; Harrison S; Seymour JF; Prince HM
Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
[TBL] [Abstract][Full Text] [Related]
52. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
[TBL] [Abstract][Full Text] [Related]
53. A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor.
Nahi H; Celanovic M; Liu Q; Lund J; Peceliunas V
Biol Blood Marrow Transplant; 2019 Jan; 25(1):34-40. PubMed ID: 30149148
[TBL] [Abstract][Full Text] [Related]
54. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Moreb JS; Byrne M; Shugarman I; Zou F; Xiong S; May WS; Norkin M; Hiemenz J; Brown R; Cogle C; Wingard JR; Hsu JW
J Clin Apher; 2018 Feb; 33(1):29-37. PubMed ID: 28556233
[TBL] [Abstract][Full Text] [Related]
55. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
[TBL] [Abstract][Full Text] [Related]
56. Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma.
Van de Wyngaert Z; Nerich V; Fouquet G; Chrétien ML; Caillot D; Azar N; Garderet L; Lenain P; Macro M; Bourhis JH; Belhocine R; Jaccard A; Karlin L; Bobin A; Moya N; Systchenko T; Gruchet C; Giraud C; Guidez S; Darras C; Princet I; Touzeau C; Moreau P; Hulin C; Deconinck E; Limat S; Leleu X;
Bone Marrow Transplant; 2020 Dec; 55(12):2254-2260. PubMed ID: 32447348
[TBL] [Abstract][Full Text] [Related]
57. Benefits of plerixafor for mobilization of peripheral blood stem cells prior to autologous transplantation: a dual-center retrospective cohort study.
Nakamura N; Jo T; Arai Y; Matsumoto M; Sakai T; Tsunemine H; Takaori-Kondo A; Arima N
Cytotherapy; 2023 Jul; 25(7):773-781. PubMed ID: 36914555
[TBL] [Abstract][Full Text] [Related]
58. Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma.
Mosevoll KA; Akkök ÇA; Hervig T; Melve GK; Bruserud Ø; Reikvam H
Cytotherapy; 2013 Jul; 15(7):850-60. PubMed ID: 23623276
[TBL] [Abstract][Full Text] [Related]
59. Mobilization of Hematopoietic Stem Cells for Hematopoietic Cells Autologous Transplantation with Use of Plerixafor.
Gawroński K; Rzepecki P; Sawicki W; Wajs J
Ann Transplant; 2017 May; 22():296-302. PubMed ID: 28496091
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of mobilization efficacy with an extended interval following plerixafor administration.
Stump SE; Trepte M; Shaw JR; Grgic T; Ptachcinski JR; Sharf A; Riches M; Shea TC; Park YA; Alexander MD
J Oncol Pharm Pract; 2020 Oct; 26(7):1590-1597. PubMed ID: 32063103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
